Published in Atherosclerosis on February 08, 2012
Astaxanthin: sources, extraction, stability, biological activities and its commercial applications--a review. Mar Drugs (2014) 1.56
Astaxanthin from Haematococcus pluvialis Prevents Oxidative Stress on Human Endothelial Cells without Toxicity. Mar Drugs (2015) 0.83
Potential Anti-Atherosclerotic Properties of Astaxanthin. Mar Drugs (2016) 0.75
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 2.89
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell (2012) 2.38
Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol (2008) 2.26
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circ Res (2006) 2.02
Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ Res (2009) 1.89
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res (2008) 1.79
Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol (2008) 1.75
Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol (2004) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Analysis of Connexin43 phosphorylated at S325, S328 and S330 in normoxic and ischemic heart. J Cell Sci (2006) 1.66
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler Thromb Vasc Biol (2013) 1.61
Concomitant coronary and multiple arch vessel stenoses in patients treated with external beam radiation: pathophysiological basis and endovascular treatment. Catheter Cardiovasc Interv (2004) 1.56
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation (2008) 1.55
The role of oxidized phospholipids in atherosclerosis. J Lipid Res (2008) 1.51
The role of innate immunity in atherogenesis. J Lipid Res (2008) 1.50
Renal frame count and renal blush grade: quantitative measures that predict the success of renal stenting in hypertensive patients with renal artery stenosis. JACC Cardiovasc Interv (2008) 1.47
Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device: is it a suture device or a "stent"? J Am Coll Cardiol (2004) 1.46
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging (2011) 1.46
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol (2011) 1.45
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol (2008) 1.36
Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem (2010) 1.35
In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. J Clin Invest (2011) 1.27
Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med (2011) 1.23
Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol (2011) 1.23
Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res (2010) 1.22
Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2007) 1.22
Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature (2013) 1.21
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation (2012) 1.21
Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell Biochem (2010) 1.20
Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res (2012) 1.18
Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol (2010) 1.17
Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol (2011) 1.16
Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem (2003) 1.13
Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev (2012) 1.13
Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis (2008) 1.13
In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol (Camb) (2012) 1.11
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res (2011) 1.09
B-cell aortic homing and atheroprotection depend on Id3. Circ Res (2011) 1.07
Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol (2013) 1.06
Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol (2012) 1.04
Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein e or low-density-lipoprotein receptor. J Nucl Med (2009) 1.04
Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J Nucl Med (2006) 1.04
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res (2005) 1.04
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04
Imaging vulnerable plaque by ultrasound. J Am Coll Cardiol (2006) 1.03
Maternal immunization programs postnatal immune responses and reduces atherosclerosis in offspring. Circ Res (2006) 1.02
Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. Prev Med (2009) 1.02
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol (2008) 1.01
Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol (2006) 1.01
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC Cardiovasc Imaging (2012) 1.00
Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol (2012) 0.99
In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes. J Am Coll Cardiol (2012) 0.98
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy (2006) 0.96
Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol (2013) 0.96
Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res (2010) 0.95
Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol (2010) 0.95
MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res (2013) 0.95
Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. J Lipid Res (2012) 0.93
Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol (2006) 0.92
Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol (2006) 0.91
Imaging of Oxidation-Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques. Curr Cardiovasc Imaging Rep (2010) 0.90
Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol (2006) 0.90
What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis? Curr Opin Lipidol (2014) 0.90
Dual roles of brain serine hydrolase KIAA1363 in ether lipid metabolism and organophosphate detoxification. Toxicol Appl Pharmacol (2007) 0.89
Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol (2012) 0.89
Recent advances in hemodynamics: noncoronary applications of a pressure sensor angioplasty guidewire. Catheter Cardiovasc Interv (2008) 0.89
Somatic cell nuclear transfer in the pig: control of pronuclear formation and integration with improved methods for activation and maintenance of pregnancy. Biol Reprod (2002) 0.87
Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis (2012) 0.84
Lipoprotein(a) accelerates atherosclerosis in uremic mice. J Lipid Res (2010) 0.84
The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med (2011) 0.84
Candidate biomarkers for the detection of coronary plaque destabilization and rupture. Curr Atheroscler Rep (2008) 0.83
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol (2005) 0.83
Organophosphate-sensitive lipases modulate brain lysophospholipids, ether lipids and endocannabinoids. Chem Biol Interact (2008) 0.83
Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics. Curr Opin Lipidol (2013) 0.83
Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. Thromb Res (2010) 0.83
Qualitative profiling and quantification of neonicotinoid metabolites in human urine by liquid chromatography coupled with mass spectrometry. PLoS One (2013) 0.82
The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis (2009) 0.82
Successful utilization of a novel aspiration thrombectomy catheter (Pronto) for the treatment of patients with stent thrombosis. Catheter Cardiovasc Interv (2006) 0.82
Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol (2002) 0.82
'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol (2015) 0.81
Treatment of recurrent pulmonary vein stenoses with endovascular stenting and adjuvant oral sirolimus. Catheter Cardiovasc Interv (2007) 0.81
Treatment of ischemic stroke complicating cardiac catheterization with systemic thrombolytic therapy. Catheter Cardiovasc Interv (2005) 0.81
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res (2012) 0.81
Spontaneous multivessel coronary vasospasm leading to cardiogenic shock. J Invasive Cardiol (2007) 0.81
Cellular function of neuropathy target esterase in lysophosphatidylcholine action. Toxicol Appl Pharmacol (2008) 0.81
Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J (2005) 0.80
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents. J Am Coll Cardiol (2008) 0.80
Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions. J Cardiovasc Transl Res (2014) 0.79
Manganese G8 dendrimers targeted to oxidation-specific epitopes: in vivo MR imaging of atherosclerosis. J Magn Reson Imaging (2014) 0.78